TY - JOUR
T1 - Unbiased detection of driver mutations in extramammary paget disease
AU - Ishida, Yoshihiro
AU - Kakiuchi, Nobuyuki
AU - Yoshida, Kenichi
AU - Inoue, Yoshikage
AU - Irie, Hiroyuki
AU - Kataoka, Tatsuki R.
AU - Hirata, Masahiro
AU - Funakoshi, Takeru
AU - Matsushita, Shigeto
AU - Hata, Hiroo
AU - Uchi, Hiroshi
AU - Yamamoto, Yuki
AU - Fujisawa, Yasuhiro
AU - Fujimura, Taku
AU - Saiki, Ryunosuke
AU - Takeuchi, Kengo
AU - Shiraishi, Yuichi
AU - Chiba, Kenichi
AU - Tanaka, Hiroko
AU - Otsuka, Atsushi
AU - Miyano, Satoru
AU - Kabashima, Kenji
AU - Ogawa, Seishi
N1 - Funding Information:
Y. Ishida reports grants from Japan Society for the Promotion of Science during the conduct of the study. N. Kakiuchi reports grants from Japan Society for the Promotion of Science during the conduct of the study. Y. Inoue reports grants from JSPS KAKENHI during the conduct of the study. H. Irie reports grants from Japan Society for the Promotion of Science during the conduct of the study. S. Matsushita reports grants and personal fees from Ono Pharmaceutical Co. Ltd; personal fees from Bristol-Myers Squibb, Maruho, MSD, Novartis, Merck Serono, and Kyowa Kirin; and grants from Kaken Pharmaceutical Co. Ltd outside the submitted work. K. Takeuchi reports personal fees from Chugai, MSD, Takeda, Janssen, Eizai, Cellgene, and Yakult and grants and personal fees from Kyowa Kirin outside the submitted work. A. Otsuka reports personal fees from Ono, BMS, Novartis, Sanofi, MSD, Torii, and Kyowa Kirin and grants and personal fees from Eisai outside the submitted work. K. Kabashima reports grants from Japan Society for the Promotion of Science during the conduct of the study. No disclosures were reported by the other authors.
Funding Information:
This work is supported by JSPS KAKENHI (JP19J12844 to Y. Ishida, 15H05909 and 19H05656 to S. Ogawa). Satoko Baba conducted FGFR1 FISH experiment. All data have been deposited at European Genome-Phenome Archive (https://ega-archive.org/) under the accession number EGAS00001004746.
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2021/3
Y1 - 2021/3
N2 - Purpose: Extramammary Paget disease (EMPD) is an uncommon skin malignancy whose genetic alterations are poorly characterized. Previous reports identified mutations in chromatin remodeling genes and PIK3CA. In order to unambiguously determine driver mutations in EMPD, we analyzed 87 EMPD samples using exome sequencing in combination with targeted sequencing. Experimental Design: First, we analyzed 37 EMPD samples that were surgically resected using whole-exome sequencing. Based on several in silico analysis, we built a custom capture panel of putative driver genes and analyzed 50 additional formalin-fixed, paraffin-embedded samples using target sequencing. ERBB2 expression was evaluated by HER2 immunohisotochemistry. Select samples were further analyzed by fluorescence in situ hybridization. Results: A median of 92 mutations/sample was identified in exome analysis. A union of driver detection algorithms identified ERBB2, ERBB3, KMT2C, TP53, PIK3CA, NUP93, AFDN, and CUX1 as likely driver mutations. Copy-number alteration analysis showed regions spanning CDKN2A as recurrently deleted, and ERBB2 as recurrently amplified. ERBB2, ERBB3, and FGFR1 amplification/ mutation showed tendency toward mutual exclusivity. Copy-number alteration load was associated with likelihood to recur. Mutational signatures were dominated by aging and APOBEC activation and lacked evidence of ultraviolet radiation. HER2 IHC/fluorescence in situ analysis validated ERBB2 amplification but was underpowered to detect mutations. Tumor heterogeneity in terms of ERBB2 amplification status was observed in some cases. Conclusions: Our comprehensive, unbiased analysis shows EMPD is characterized by alterations involving the PI3K-AKT pathway. EMPD is distinct from other skin cancers in both molecular pathways altered and etiology behind mutagenesis.
AB - Purpose: Extramammary Paget disease (EMPD) is an uncommon skin malignancy whose genetic alterations are poorly characterized. Previous reports identified mutations in chromatin remodeling genes and PIK3CA. In order to unambiguously determine driver mutations in EMPD, we analyzed 87 EMPD samples using exome sequencing in combination with targeted sequencing. Experimental Design: First, we analyzed 37 EMPD samples that were surgically resected using whole-exome sequencing. Based on several in silico analysis, we built a custom capture panel of putative driver genes and analyzed 50 additional formalin-fixed, paraffin-embedded samples using target sequencing. ERBB2 expression was evaluated by HER2 immunohisotochemistry. Select samples were further analyzed by fluorescence in situ hybridization. Results: A median of 92 mutations/sample was identified in exome analysis. A union of driver detection algorithms identified ERBB2, ERBB3, KMT2C, TP53, PIK3CA, NUP93, AFDN, and CUX1 as likely driver mutations. Copy-number alteration analysis showed regions spanning CDKN2A as recurrently deleted, and ERBB2 as recurrently amplified. ERBB2, ERBB3, and FGFR1 amplification/ mutation showed tendency toward mutual exclusivity. Copy-number alteration load was associated with likelihood to recur. Mutational signatures were dominated by aging and APOBEC activation and lacked evidence of ultraviolet radiation. HER2 IHC/fluorescence in situ analysis validated ERBB2 amplification but was underpowered to detect mutations. Tumor heterogeneity in terms of ERBB2 amplification status was observed in some cases. Conclusions: Our comprehensive, unbiased analysis shows EMPD is characterized by alterations involving the PI3K-AKT pathway. EMPD is distinct from other skin cancers in both molecular pathways altered and etiology behind mutagenesis.
UR - http://www.scopus.com/inward/record.url?scp=85103379861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103379861&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-20-3205
DO - 10.1158/1078-0432.CCR-20-3205
M3 - Article
C2 - 33323405
AN - SCOPUS:85103379861
SN - 1078-0432
VL - 27
SP - 1756
EP - 1765
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 6
ER -